Abstract
Introduction Long COVID, a new condition whose origins and natural history are not yet fully established, currently affects 1.5 million people in the UK. Most do not have access to specialist long COVID services. We seek to optimise long COVID care both within and outside specialist clinics, including improving access, reducing inequalities, helping patients manage their symptoms effectively at home, and providing guidance and decision support for primary care. We aim to establish a ‘gold standard’ of care by systematically analysing symptom clusters and current practices, iteratively improving pathways and systems of care, and working to disseminate better practices.
Methods and analysis This mixed-method, multi-site study is informed by the principles of applied health services research, quality improvement, co-design, and learning health systems. It was developed in close partnership with patients (whose stated priorities are prompt clinical assessment; evidence-based advice and treatment; and help with returning to work and other roles) and with front-line clinicians. Workstreams and tasks to optimise assessment, treatment and monitoring are based in three contrasting settings: [1] specialist management in 10 long COVID clinics across the UK, via a quality improvement collaborative, experience-based co-design and targeted efforts to reduce inequalities of access; [2] patient self-management at home, with technology-supported monitoring; and [3] generalist management in primary care, harnessing electronic record data to study population phenotypes and develop evidence-based decision support, referral pathways and prioritisation criteria across the primary-secondary care interface, along with analysis of costs. Study governance includes an active patient advisory group.
Ethics and dissemination LOCOMOTION is sponsored by the University of Leeds and approved by Yorkshire & The Humber - Bradford Leeds Research Ethics Committee (ref: 21/YH/0276). Dissemination plans include academic and lay publications, and partnerships with national and regional policymakers to influence service specifications and targeted funding streams.
Study registration ClinicalTrials.gov: NCT05057260; ISRCTN15022307.
Competing Interest Statement
Manoj Sivan is advisor to the World Health Organisation (WHO) for Long COVID policy in Europe. Trisha Greenhalgh is member of the UK Long Covid national task force and member of the National Institute for Health and Care Excellence (NICE) post-acute COVID guideline oversight committee and Independent SAGE member. Simon de Lusignan is the Director of the Oxford-RCGP RSC (primary care surveillance network); has received grants through his University from AstraZeneca, Eli Lilly, GSK, MSD, NovoNordisk, Sanofi, Seqirus and Takeda; and has sat on advisory boards for AstraZeneca, Sanofi and Seqirus. Clare Rayner Member of Society of Occupational Medicine Taskforce on long COVID; member of WHO guideline development group on rehabilitation for post COVID condition; community representative on the Access to COVID-19 Tools Accelerator (ACT-A) committee; member of long COVID support employment group (unpaid advocacy work for workers with long COVID); and has undertaken paid work for Nestle, advising on support for employees with long COVID.
Funding Statement
This research is supported by National Institute for Health Research (NIHR) Long Covid grant [Ref COV-LT-0016] with University of Leeds as the lead organisation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
LOCOMOTION is sponsored by the University of Leeds and approved by Yorkshire & The Humber - Bradford Leeds Research Ethics Committee (ref: 21/YH/0276). Dissemination plans include academic and lay publications, and partnerships with national and regional policymakers to influence service specifications and targeted funding streams.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(joint 1st author)
Funder: National Institute for Health Research (NIHR) Ref COV-LT-0016
m.sivan{at}leeds.ac.uk
trish.greenhalgh{at}phc.ox.ac.uk
nawar.bakerly{at}srft.nhs.uk
m.barahona{at}imperial.ac.uk
alex.casson{at}manchester.ac.uk
j.clarke{at}imperial.ac.uk
vasa.curcin{at}kcl.ac.uk
julie.darbyshire{at}phc.ox.ac.uk
helen.davies30{at}wales.nhs.uk
h.dawes{at}exeter.ac.uk
brendan.delaney{at}imperial.ac.uk
carlos.echevarria{at}nhs.net
sarah.elkin{at}nhs.net
re66{at}leicester.ac.uk
zfalope{at}nhs.net
ben.glampson1{at}nhs.net
d.c.greenwood{at}leeds.ac.uk
stephen.halpin{at}nhs.net
m.c.horton{at}leeds.ac.uk
joseph.kwon{at}phc.ox.ac.uk
simon.delusignan{at}phc.ox.ac.uk
gayathri.delanerolle{at}phc.ox.ac.uk
e.mayer{at}imperial.ac.uk
hmaster{at}nhs.net
r.milne{at}soton.ac.uk
g.mir{at}leeds.ac.uk
jymorris{at}dundee.ac.uk
d.b.oconnor{at}leeds.ac.uk
r.j.o'connor{at}leeds.ac.uk
amy.parkin1{at}nhs.net
stavros.petrou{at}phc.ox.ac.uk
anton.pick{at}ouh.nhs.uk
n.preston{at}leeds.ac.uk
clarerayner{at}clara.co.uk
a.k.rebane{at}leeds.ac.uk
nikki.smith{at}forensic-science.uk.net
emma.tucker{at}oxfordhealth.nhs.uk
a.espinosagonzalez15{at}imperial.ac.uk
sareeta.baley{at}nhs.net
annette.rolls{at}nhs.net
emily.bullock{at}nca.nhs.uk
megan.ball{at}nhs.net
shehnaz.bashir{at}nhs.scot
m.mansoubi{at}exeter.ac.uk
j.m.elwin{at}dundee.ac.uk
denys.prociuk16{at}imperial.ac.uk
iram.n.qureshi{at}uhl-tr.nhs.uk
samantha.jones1a0ee{at}wales.nhs.uk
Data Availability
We will use Open Science Framework (OSF) to share of all research outputs, including data, codes, and other types of information that has the potential to aid the advancement of scientific progress and benefit other researchers by adding transparency to the research process. Data items from individual studies will be shared in relevant consortium institutional repositories (the University of Leeds public data repository for studies led by Leeds) to increase exposure. The OSF will consist of two levels: a data dictionary with basic info about the study, and the more detailed dataset (for further analysis / meta-analysis). Data will be issued with a Digital Object Identifier (DOI) which will allow it to be referenced and to make it easier for others to identify and access relevant files.